Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)

被引：3
|
作者：
Bekaii-Saab, T. S.
Bendell, J. C.
Cohn, A. L.
Hurwitz, H.
Kozloff, M.
Roach, N.
Tezcan, H.
Feng, S.
Sing, A.
Grothey, A.
机构：
[1] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Ingalls Hosp, Harvey, IL USA
[6] Univ Chicago, Harvey, IL USA
[7] C3, Alexandria, VA USA
[8] North Idaho Canc Ctr, Coeur Dalene, ID USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3595
引用
收藏
页数：2
相关论文
共 50 条
  • [1] BEVACIZUMAB PLUS CHEMOTHERAPY IN 2ND LINE METASTATIC COLORECTAL CANCER (MCRC): INITIAL RESULTS FROM ARIES, A SECOND BEVACIZUMAB OBSERVATIONAL COHORT STUDY (OCS)
    Bekaii-Saab, T.
    Bendell, J.
    Cohn, A.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 20 - 20
  • [2] Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS)
    Kozloff, M.
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Hurwitz, H.
    Roach, N.
    Tezcan, H.
    Fish, S.
    Flick, E. D.
    Mun, Y.
    Dalal, D.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Kozloff, M. F.
    Roach, N.
    Sargent, D. J.
    Tezcan, H.
    Grothey, A.
    Purdie, D. M.
    Sugrue, M. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Initial results from aries, a multi-indication bevacizumab observational cohort study (OCS). Characteristics of metastatic colorectal cancer patients receiving BV and chemotherapy (CT) in 2nd line
    Bekaii-Saab, T.
    Grothey, A.
    Bendell, J.
    Cohn, A.
    Kozloff, M.
    Roach, N.
    Sargent, D.
    Tezcan, H.
    Purdie, D.
    Sugrue, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [6] Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS)
    Cohn, Allen Lee
    Hurwitz, Herbert
    Bekaii-Saab, Tanios S.
    Bendell, Johanna C.
    Kozloff, Mark
    Tezcan, Haluk
    Flick, Elizabeth Dawn
    Mun, Yong
    Fish, Susan
    Dalal, Darshan
    Grothey, Axel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP)
    Cohn, A. L.
    Bekaii-Saab, T.
    Bendell, J. C.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (MCRC): Results from the BRiTE observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Purdie, D.
    Berlin, J.
    Flynn, P.
    Kabbinavar, F.
    Sargent, D.
    Dong, W.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [9] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study
    Kozloff, M. F.
    Sugrue, M. M.
    Purdie, D. M.
    Berlin, J. D.
    Flynn, P. J.
    Kabbinavar, F. F.
    Sargent, D. J.
    Dong, W.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany
    Arnold, D.
    Kindler, M.
    Petersen, V.
    Tummes, D.
    Moelle, M.
    Schoeberl, C.
    Srock, S.
    Kutscheidt, A.
    Grothe, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : CP19 - U123
12345